2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.33 Babu

PP01.33 Babu - Abstract

Pdf Summary

In a phase I clinical trial exploring the combination of ceritinib and docetaxel for ALK-negative, EGFR WT advanced non-small cell lung cancer, 21 patients were enrolled. The study aimed to determine the recommended phase 2 dose (RP2D) and evaluate safety and efficacy. The most common adverse events included fatigue, alopecia, diarrhea, anemia, and nausea. Median progression-free survival (PFS) was 4.7 months, and median overall survival (OS) was 8.0 months. Patients who received the treatment as a second line had a longer median OS compared to those who received it third line and beyond. Overall response rate (ORR) was 14.3%, and disease control rate (DCR) was 61.9%. The RP2D was determined to be docetaxel 75 mg/m2 IV q3 weeks and ceritinib 150 mg PO daily. The toxicity profile was consistent with known data, and while some clinical activity was observed, response rates and survival outcomes did not significantly differ from established treatments using docetaxel. Further research may be needed to enhance the efficacy of this combination therapy for NSCLC patients.

Keywords

ceritinib

docetaxel

ALK-negative

EGFR WT

non-small cell lung cancer

phase 1 clinical trial

recommended phase 2 dose

progression-free survival

overall survival

adverse events